Resuscitation: Past Beliefs and Current Clinical Trials

David B. Hoyt, MD FACS
Executive Director
American College of
Surgeons
Chicago, IL




Resuscitation

- Goals of treatment have evolved
 - Volume resuscitation
 - Oxygen delivery
 - Hemostasis

Spectrum: Saline to Fresh Whole Blood





 For centuries theories concerned spirits to explain disease.






The error in reasoning

- A man gets sick: he takes medicine: he gets well
 - Something happens after another
- Does not mean the second happened because of the first.
- "Post hoc Ergo propter hoc"
- After it; therefore because of it

Resuscitation – Greek Medicine

- Homer the Iliad 800 BC
 - 147 wounds described
 - 114 died
- Mortality 77%
 - Treatment
 - Application of herbs
 - Removing arrows
 - Casting fractures






Galen – Blood letting

- Born 131 AD
 - MD training 149 AD
- Galen's Theory
 - Food to liver→ blood → artery → heart → veins
- Draining blood "therapeutic"



Roman Military Care: Organized System





Avicenna's Canon – 980-1037 Medical Encyclopedia

"it should be used in it's natural state upon uncomplicated disease....that two opposed cases be observedand that study be made of the time of action and of the reproducibility of the effects......the experimentation must be done with the human body for testing a drug on a lion or a horse might not prove anything about it's effect on man"

The Modern Clinical Trial


Franciscan Roger Bacon: Apology


- "for it is exceedingly difficult and dangerous to perform operations on the human body....for the practical sciences which do their work on the insensate bodies can multiply their experiments till they get rid of deficiency and errors...but a physician cannot do this because of the nobility of the material in which he works....physicians are to be excused for their defects more than are workers in the sciences"
- Endorsement of empiric therapy...- 1275AD

Medicine Returns to Europe




- 1010- Constantine of Carthage
 - Learned medicine in Arabia and India mistrusted
- Escaped to Salerno
 - Translated Arabic to Latin
- First medical school -Return of Dissection





Early Gun Shot Wounds

- -
 - Pare` 1507- focus infection
 - Poisoned gunpowder
 - Boiling oil "diseases not curable by knife were curable by fire"
 - New Concept -Turpentine and Rosehips





Barber - Surgeons

1492- Blood Letting Calendar Second publication Gutenberg press

Critical Development: Anatomy Vesalius - Rejected

- 1534- Company-Guild joined
 - Henry VIII
- Given 4 executed criminals/year for dissection




- 1543 De Fabrica Humani Corporis – 300 woodcuts
 - Pupils left, burned his manuscripts, gave up anatomy
- Could not explain R → L passage of blood.



Critical Development Physiology: Galileo - 1581

- Imprisoned by Pope for views about earth orbiting sun
- Medical School @ Pisa
- Watched pendulum
 - Timed pulse



Critical Development Anatomy Meets Physiology

- Harvey challenged Galen
 - No pores in the heart
 - Demonstrated venous return
 - Calculated ejection volume HR x 60cc x 1440 minutes
 - 16 tons in 24 hours impossible
 - 1628 Must circulate






Right time - Right place Experimental Philosophy Club

- 1630's-1650's Oxford
 - Harvey member
- Wren-Architect
 - Quill and bladder syringe
- Boyle-Chemist
- Injected antimony and opium in dogs
 - Vomiting and Sedation

Intravenous injections circulate



First Transfusion

- 1665 Lower
 - Wren and Boyle medical student
- Dog shock model and resuscitation
 - Artery to vein
- "One animal may live with the blood of another"



Blood Transfusion History

- Jean Batista Denys
 - December 19, 1667
- Transfused Antoine Maury
 - lambs blood
 - Third transfusion
 - Died, wife sued
 - Trial Absolved Denys
- French Parliament and Pope banned transfusion





The last the last the last










Continued practice

Crystalloid - Colloid History


- 1831-O'Shaughnessy
 - Described cholera deficit
- 1832-Latta
 - Gave normal saline
- 1882-Ringer
 - Described components
- 1898-Thomas
 - Obstetrical hemorrhage
- 1910's Colloid: Gum of acacia
- 1931-Hartman
 - Sodium lactate added





First Operative Transfusion

- 1908-Carrel summoned by Lambert
 - Brothers (surgeons)
- Father to baby transfusion success
 - Carrel no license
 - Celebrated birthday 21 years later





- Landsteiner Vienna
- 1900 Published work
- 1912 Ottenberg
 - Mt Sinai simplified test
 - Reduced hemolysis to zero.

- 1915 Lewisohn Mt. Sinai
 - Na citrate
- "The technique of blood transfusion...was suddenly made as simple...as saline infusion..."









Shock Theory -Walter Cannon

- Studied American Forces
- MD physiologist Harvard
- Traumatic Shock
 - Shock dilated capillary region – exemia
 - Neuro-endocrine theories confused volume resuscitation role



Cannon - World War I

- "The injection of a fluid that will increase blood pressure has dangers in itself. Hemorrhage may not have occurred to a marked degree because the blood pressure has been too low to overcome the obstacle offered by a clot."
- "Pop the Clot"

"with this method of blood transfusion, I know that at this hospital we have saved lives by its use which would otherwise have been lost....

Lieutenant A. M. Hansen to Dr. Cannon 1918



Shock Theory-Alfred Blalock

- 1925 Joined Harrison
 - Vanderbilt Chief Residents
 - Vivien Thomas 1929
- Defined relationship of blood loss to shock
- Volume resuscitation critical
- Theory largely ignored for 30 Years



1924-5 Global Instability





Colloid Resuscitation - WW II

- Blood needed Carrel asked
- Blood would not survive the transatlantic journey
- Shifted focus plasma
 - Committee on Transfusion 1940 - Walter B. Cannon
- Albumin first used
 - Pearl Harbor- I. Ravdin



World War II

- 1943 Churchill- Harvard
 - "Plasma not a blood substitute"
- Described over zealous shock resuscitation
- Pushed for blood with great personal political risk





Korea Blood Program

- Military program collapsed
- No blood first 70 days
- First changes in coagulation reported
 - Small transfusion volumes



Vietnam-Coagulation Disorders



- First description: coagulopathy
- Described relation of shock and acidosis
- 9% of massive transfusions
 - Simmons and Collins





Hx Coagulapathy Treatment


- Needs as function of blood volume loss
 - Volume
- @ 0.2 BV
- Red Cells
- @ 0.6 BV
- Albumin
- @ 1.2 BV
- Coag fact.
- @ 1.8 BV
- Platelets
- @ 2.2 BV

- Treatment by component in order
 - Volume
 - Red cells
 - Albumin
 - Coagulation factors
 - Platelets

1960s - Civilian Use



- Blood like oil wildcatters
- Unregulated
 - Fractionation for drugs
 - Big money
- Inappropriate collection
 - rampant
- Hepatitis emerged
- AIDS not yet present



Collins 1974


1970s: Crystalloid: 3 TO 1

- Original studies
 - Shires, 1963
 - Three isotope model
- Extracellular repletion essential for survival



Trends in Resuscitation:1980s Goal Directed Oxygen Delivery

- Supernormal O₂ del.
 - Shoemaker et al.
- 7 randomized studies no difference
- IncreasedCompartmentSyndromes



Significant Developments Trauma Systems

- Paramedic Training
- Regional EMS systems
- ATLS
- Trauma Care standards
- Verification



New Concept Damage Control

- Damage Control Surgery
 - Operational logistics
 - Shunts
 - Stapling bowel and lung temporary
 - Solid organ tamponade temporary
 - Temporary closure






Saw sicker patients earlier

Factors

Triggers

- Factors
 - Hypothermia
 - Acidosis
 - Coagulopathy
- Triggers
 - Transfusion of 10 units
 - Decreased platelets
 - PT of >16 secs
 - PTT of >50 secs
 - Diffuse nonsurgical bleeding



Strategy

- Staged Decisions in Management
 - I Pt selection indications
 - II Intraoperative assessment
 - III Physiologic restoration
 - Coagulation control
 - IV Return-operating room
 - V Abdominal closure



NIH Trauma Working Group

- Expand Basic, Translational, and Applied Focused Research
- Trauma Working Group July 14th -15th,2003
- NHLBI, NIGMS, NINDS, NICHD
 - Cosponsored by ACSCOT, DOD, CDC, FDA, AAST
- Scope:
 - 70 scientists and clinicians
 - Gaps/frontiers in basic science of injury
 - Areas ready for translational research

Goals: 1)National Center for Resuscitation Research 2)Build a multicenter network for clinical trials


Critical events - 2003





RFA 2004

Resuscitation Research Network






Resuscitation Strategies 2018

- Should we resuscitate
- Ringer's lactate and NS
- HTS
- Colloids
- Hemoglobin solutions
- Blood
- Other additives or strategies



The Question

While there is still a hole in a named blood vessel, what is the best fluid resuscitation strategy to keep the victim alive until hemostasis can be achieved, and to promote intact survival?



| | N | 24-Hour Mortality | |
|----------|----|-------------------|------|
| | | N | % |
| Limited | 96 | 5 | 5.2 |
| Standard | 95 | 14 | 14.7 |



2015 - Low vs. Conventional Resuscitation Trial Completed

- ROC pilot field and early ED
- 250cc vs. normal
 - Hypotensive pts
- Challenge get difference in two groups






BLAST -2015

Biomarker
Lactate
Assessment of
Shock in
Trauma
compared point of
care lactate to
BP<90 to predict
resuscitative
care





| - 1 | AUC (95% CI) | | |
|-------|------------------|------------------|--|
| | Ground | Air | |
| -LAC | 0.78 (0.73-0.83) | 0.66 (0.58-0.73) | |
| ВР | 0.59 (0.53-0.66) | 0.49 (0.42-0.57) | |
| Value | < 0.001 | 0.004 | |



Resuscitation Strategies 2018


- Should we resuscitate
- Ringer's lactate and NS
- HTS
- Colloids
- Hemoglobin solutions
- Blood
- Other additives or strategies



Fluid **Type** Concerns



- Concerns with R.L. and NS
 - Pro-inflammatory
 - Hyperchloremic acidosis
- HTS -Immunologic advantage
 - 1984 attempting to isolate shock factor with affinity chromatography and t-cell suppression – NACL eluent +++
 - Logistic advantage
 Higher pressure for same volume





Immune

suppression

hemorrhage. trauma or burn

TSFs

Senescent Signaling

APC + antigen

ERK

nuclear factors



osmoreceptor

MAPK p38

nucleus



Recovery

mechanism

Junger,

1997




In vivo Effects


Does early fluid type effect MOF?



- Animal model 2hit
 - Hemorrhage
 - Peritonitis
- Outcomes
 - Survival
 - Organ function
- Survival
 - HTS group 76.9%
 - RL group 14.3%

Coimbra, 1997














- Decreases neutrophil L selectin expression, not endothelial P and E
- CD 11b unchanged
 - Angle,1998
- HTS vs. RI -Decreased H₂O₂
 - Angle,1998
 - Rhee, 1998





HTS Effects- Humans

- 4ml/kg 7.5% over 15 min.
- Immune function studied
 - Angle, 2000











Phase II trial 2005



ARDS-free Survival



N=209

Unadjusted HR: 0.75 (95% CI: 0.49-1.15)


Log rank: p=0.16

NIH, R01HL73233-01, Bulger et al, Arch Surg 2008

Massive transfusion subgroup




Phase III Trial - 2010 28 day survival




| Treatment | 28 day survival |
|-----------|-----------------|
| HSD | 74.5% |
| HS | 73.0% |
| NS | 74.4% |
| P value | 0.91 |

Immune Effects Realized





- CoTCCC 2001 & 2010
 - Hetastarch chosen
 - Logistic advantage
 - Guidelines not really followed –
 60% get RL or NS
- Multiple studies (> 50)
 - Albumin equal other colloids
 - Colloids equal to crystalloid






Resuscitation Strategies 2018

- Should we resuscitate
- Ringer's lactate and NS
- HTS
- Colloids
- Hemoglobin solutions
- Blood
- Other additives or strategies



Human Polymerized Hemoglobin Ambulance Infusion









500ml, 10g/dl P50 = 28-30 torr T1/2 = 1 day Shelf-life > 1 year



Results: Study Overall

714 patients 82 patients died



349 Received
PolyHeme®
46 Deaths (13%)

365 Received
Control
36 Deaths (10%)

NO Difference

Resuscitation Strategies 2018

- Should we resuscitate
- Ringer's lactate and NS
- HTS
- Colloids
- Hemoglobin solutions
- Blood
- Other additives or strategies






Weve Had a Debate

- When to use:
 - Fresh whole blood
 - Whole blood
 - Fresh frozen plasma
 - Platelets
 - Cryoprecipitate
 - Fibrinogen



You Can Get Close With Reconstitution



Component Therapy 1U PRBC + 6U PLT + 1U FFP + 10 pk Cryo

- ·Hct 29%
- Plt 87K
- Coag activity 65%
- •750 mg fibrinogen

*Armand & Hess, Transfusion Med. Rev., 2003



Fibrinogen



Historical View

- Measure coagulation and platelet counts
- Give plasma when INR or aPTTr > 1.5
- Give platelets when platelet count < 50K
- Give cryoprecipitate or fibrinogen when fibrinogen is < 100 mg/dL
 - College of American Pathologists
 - English National Blood Service





Historical View

- Measure coagulation and platelet counts
- Give plasma when INR or aPTTr > 1.5
- Give platelets when platelet count < 50K
- Give cryoprecipitate or fibrinogen when fibrinogen is < 100 mg/dL
 - College of American Pathologists
 - English National Blood Service



Iraq – Early Aggressive Whole Blood Restoration





PROPER Trial Completed — data May 2014


JAMA Feb 2015

Conclusions and Relevance Among patients with severe trauma and major bleeding, early administration of plasma, platelets, and red blood cells in a 1:1:1 ratio compared with a 1:1:2 ratio did not result in significant differences in mortality at 24 hours or at 30 days. However, more patients in the 1:1:1 group achieved hemostasis and fewer experienced death due to exsanguination by 24 hours. Even though there was an increased use of plasma and platelets transfused in the 1:1:1 group, no other safety differences were identified between the 2 groups.

Resuscitation Strategies 2018


- Should we resuscitate
- Ringer's lactate and NS
- HTS
- Colloids
- Hemoglobin solutions
- Blood
- Other additives or strategies

Need new strategies




Shock and Gut Ischemia

- Shock structured hierarchy of ischemia
- Gut first to go down and last to resuscitate
- Often seen as source of systemic activation of inflammation
- Lymph factors postulated



PMN Activation After Shock




Critical step postulated for MOF

Triggers of Cell Activation

- Inflammatory mediators (bacterial/viral/fungal sources, endotoxins, cytokines, histamine, oxidized products, complement fragments, LTB₄, PAF, etc.)
- Depletion of anti-inflammatory mediators
- Fluid shear stress
- Oxygen Gas Pressure Transitions
- Temperature Transitions


New Hypothesis



 Gut ischemia allows activated pancreatic proteases in gut lumen to attack intestinal wall producing inflammatory activators

Theory 1: Excessive Macrophage Stimulation Liver and Lung

- Translocation endotoxin
- Direct hepatic macrophage stimulation
- Excessive production
 - TNF
 - IL-1
 - IL-6




Clinical evidence inconsisten

Inflammatory activation

Adtivation

- Gut PMN sequestration and priming: PLA₂
 - Metastatic adhesion to enflamed endothelium
 - Local enzymatic and oxygen free radical destruction



Blocking not clinically effective

Theory 2: Ischemia, Reperfusion: PMN

Autodigestion hypothesis




Normal intestine

Ischemic intestine



 Containment of activated pancreatic digestive enzymes




- Breakdown of mucosal barrier
- Leak of pancreatic enzymes



Is there a useful intervention against the destructive action of pancreatic digestive enzymes in the ischemic intestine?

Computer Model Initial Bleeding Rate (mmHg) - 1.0 L/min 80 --- 0.1 L/min Mean Arterial Pressure 60 50 40 30 20 10 0 20 30 40 50 10 Time (min)




Physiologic 20

Hirshburg, Hoyt, Mattox, J. of Trauma 60(6) 1221-7, 2006

Methods: Classes of Proteinase Inhibitors

- Serine Proteinases (pancreatic enzymes)
 - Natural plasma inhibitors:
 - alpha-2-Macroglobulin
 - · alpha-1-antichymotrypsin
 - alpha-1-antitrypsin
 - Chemical modifiers:
 - DFP and PMSF are serine group specific, but toxic.
 - Pseudo-substrate enzyme specific inhibitors
 - . TPCK (chymotrypsin) and
 - TLCK (trypsin)
 - Pseudo substrate <u>broad</u> <u>spectrum</u> inhibitor
 - Nafamosat

- Cystein Proteinases (cathepsins)
 - alkylating agents
 - peptidyl-fluoromethylketones
 - cystatins
- Metallo Proteinases (MMPs)
 - EDTA and TIMPs
- Aspartyl Proteinases (phospholipases A2, pepsin)
 - pepstatin, structure specific statine-based analogues





Inhibition Activity

Intestinal H&E Histology










Sham Shock

Shock


Shock - inhibition

Anatomy preserved

Serine Protease Inhibitor in PEG with Electrolytes vehicle Improves Morbidity




In situ zymography – MMP9



Critical Metalloprotease Activation Avoided


In a Mini-Pig Model of Hemorrhagic Shock, Tranexamic Acid Improves Clinical Outcomes



Clinical Score

4.0 3.0 2.0 1.0 0

Normal Behavior Mild Injury Moderate Injury Severe Injury Morbid



A Different Strategy LB1148



- Oral small-molecule therapeutic
 - Active ingredient: tranexamic acid
 - Used as bowel prep
 - Inhibits 17 digestive enzymes: Prevents damage to the intestine and adhesion formation
 - Preserves bowel function
 - Reduces hospital stay ,post-op complications
- Known safety profile
 - FDA-approved components
 - 505(b)2 regulatory pathway
- Patented formulation




Preoperative LB1148 Prevented Abdominal Adhesions in Rat

Vehicle Treated


Vehicle LB1148

LB1148 Improves postop GI function




91

Phase 2: Cardiovascular Surgery LB1148 –return of function








92


Company Activities and Timelines



^{*} With adequate capital trial can commence enrollment within 2-3 weeks.


Selected Financial Data

Mix of non-dilutive and private financings



- Raising \$20M to \$25M intuitional pre-IPO financing round. This funding will carry LBS through multiple phase 2 data readouts.
- With positive phase 2 data readouts in mid-2018 LBS will pursue an IPO in Q3.

The Hartford Consensus







The Hartford Consensus IV:

A Call for Increased National Resilience nd the jo BLEEC

Arrainan Cirates or Francisco

Supering Quality.

Higher Stamman, States Chausean

BLEEDING CONTROL. ORG

O STOP THE BLEED SAVE A LIFE

About

Hartford Consen

Partners

blic Fin

200

Website: BLEEDING CONTROL.ORG


Public Course, National Focus PSA – OCT 2016







National Academy of Medicine





- 2016 Calls for Zero
 Preventable Deaths
 - ACS Sponsor
- National Implementation Strategy
 - Sharing of Civilian and Military Systems Approach
- Nov 1-2, 2016





Conclusions

- We have ambivalence about resuscitation
- Religion, economics, war time logistics and our knowledge of shock have influenced practice
- The study of wartime injuries has changed medical practice repeatedly



Conclusions

- Early coagulopathy is real
 - need early indicators
- The reconstitution of blood is likely to save lives
- Targeting gut end organ response holds promise
- Clinical trials and reevaluation of protocols make this clearer it is the only way

